Concurrent Session: Success and Challenges with Allogeneic CAR T
Saturday, September 9, 2023 04:30 PM - 05:30 PM
Grand Ballroom L
Chair
Jason Bock, PhD, CTMC, USA
Speakers
Lou Bartolo, DNP, MSN, RN, NMDP, USA – Overcoming Regulatory Challenges of Allogeneic CAR T
Charles Mooney, MBA, MS, MT(ASCP)SBB, Oklahoma Blood Institute and BioSharing Network, USA – PBMS Donor Recruitment, Selection, Collection and Retention Strategies
Sarah Nikiforow, MD, PhD, Dana-Farber Cancer Institute, USA – Ramifications for clinical sites - autologous versus allogeneic CAR T cells products and trials
Clinical overview and challenges. Successes and Challenges with Allogeneic CAR T - Clinical protocols, donor identification and requirements, comparability, what defines an allogeneic product?
Session Objectives
Allogeneic therapies offer the promise of addressing many of the manufacturing and supply chain difficulties, but they also carry some of their own underappreciated challenges. This panel will discuss those as well as strategies to mitigate these in the development process, regulatory interactions, and donor identification.
Jason Bock, PhD, CTMC, USA
Speakers
Lou Bartolo, DNP, MSN, RN, NMDP, USA – Overcoming Regulatory Challenges of Allogeneic CAR T
Charles Mooney, MBA, MS, MT(ASCP)SBB, Oklahoma Blood Institute and BioSharing Network, USA – PBMS Donor Recruitment, Selection, Collection and Retention Strategies
Sarah Nikiforow, MD, PhD, Dana-Farber Cancer Institute, USA – Ramifications for clinical sites - autologous versus allogeneic CAR T cells products and trials
Clinical overview and challenges. Successes and Challenges with Allogeneic CAR T - Clinical protocols, donor identification and requirements, comparability, what defines an allogeneic product?
- Donor challenges
- Regulatory challenges
- Product specific challenges
Session Objectives
Allogeneic therapies offer the promise of addressing many of the manufacturing and supply chain difficulties, but they also carry some of their own underappreciated challenges. This panel will discuss those as well as strategies to mitigate these in the development process, regulatory interactions, and donor identification.
Charles Mooney MBA, MS, MT(ASCP)SBB
Vice-President, Research & BioDevelopment
Oklahoma Blood Institute and BioSharing Network
Speaker
Vice-President, Research & BioDevelopment
Oklahoma Blood Institute and BioSharing Network
Speaker
Sarah Nikiforow MD, PhD
Asst Professor, Stem Cell Transplantation Program, Asst. Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Program
Dana-Farber Cancer Institute
Speaker
Asst Professor, Stem Cell Transplantation Program, Asst. Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Program
Dana-Farber Cancer Institute
Speaker